To assess the efficacy of early thrombolytic therapy with recombinant tissue-type plasminogen activator in the treatment of acute ischemic stroke and to assess the feasibility of conducting a larger, multi-center trial.
- Tissue plasminogen activator (Activase®)Drug
Intervention Desc: Thrombolytic
Randomized, stratified, double-blind, placebo-controlled trial of 27 patients. Stratification was by whether treatment was begun within 90 minutes or 91 to 180 minutes from onset.
Patients were randomized to receive either 0.85 mg/kg r-TPA of placebo.
|Type||Measure||Time Frame||Safety Issue|
|Primary||Proportion of patients in each group who improved by 4 or more points on the National Institutes of Health Stroke Scale at 24 hours.|